SpringWorks Therapeutics, Inc. - common stock (NQ:SWTX)

46.99 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist

Price and Volume

Volume	0
Open	46.99
Bid (Size)	46.98 (1,217)
Ask (Size)	47.00 (16)
Prev. Close	46.99
Today's Range	46.99 - 46.99
52wk Range	46.99 - 46.99
Shares Outstanding	49,127,913
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

October 21, 2025

Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and...

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

August 18, 2025

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

Performance

More News

Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts ↗

February 24, 2025

Via Benzinga

Legendary Investor Stanley Druckenmiller Made Huge AI And Chipmaker Bets In Q2 — Here's What He Knows That You Don't ↗

August 18, 2025

Via Benzinga

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

July 18, 2025

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know ↗

July 11, 2025

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders

June 15, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SWTX, ICAD, SSBK on Behalf of Shareholders

June 04, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 03, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

May 23, 2025

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders

May 18, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders

May 18, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

April 30, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders

April 30, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Analyst Expectations For SpringWorks Therapeutics's Future ↗

April 28, 2025

Via Benzinga

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion ↗

April 28, 2025

Via Benzinga

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

April 28, 2025

From Ademi & Fruchter LLP

Via Business Wire

SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders

April 28, 2025

From Halper Sadeh LLC

Via Business Wire

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

April 28, 2025

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

April 27, 2025

From SpringWorks Therapeutics, Inc.

Via GlobeNewswire

SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout ↗

April 24, 2025

Via Stocktwits

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week ↗

March 16, 2025

Via Stocktwits

SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest? ↗

March 10, 2025

Via Stocktwits

No Quick Fix For This Market ↗

March 23, 2025

Via Talk Markets

10 Health Care Stocks Whale Activity In Today's Session ↗

February 27, 2025

Via Benzinga

Frequently Asked Questions

Is SpringWorks Therapeutics, Inc. - common stock publicly traded?

Yes, SpringWorks Therapeutics, Inc. - common stock is publicly traded.

What exchange does SpringWorks Therapeutics, Inc. - common stock trade on?

SpringWorks Therapeutics, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for SpringWorks Therapeutics, Inc. - common stock?

The ticker symbol for SpringWorks Therapeutics, Inc. - common stock is SWTX on the Nasdaq Stock Market

What is the current price of SpringWorks Therapeutics, Inc. - common stock?

The current price of SpringWorks Therapeutics, Inc. - common stock is 46.99

When was SpringWorks Therapeutics, Inc. - common stock last traded?

The last trade of SpringWorks Therapeutics, Inc. - common stock was at 06/30/25 04:00 PM ET

What is the market capitalization of SpringWorks Therapeutics, Inc. - common stock?

The market capitalization of SpringWorks Therapeutics, Inc. - common stock is 2.31B

How many shares of SpringWorks Therapeutics, Inc. - common stock are outstanding?

SpringWorks Therapeutics, Inc. - common stock has 2B shares outstanding.